Parkinson's disease Nervous System Diseases Parkinson's disease
Conditions
Interventions
Open label use of buspirone together with L-dopa in an aim to alleviate dyskinesias and to study the role of serotonergic terminals in L-dopa induced dyskinesia with PET.
Visit 1: Patients will take
Sponsors
Imperial College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Parkinson's disease patients and healthy individuals Parkinson's disease patients 1. Age between 50-80 2. Were diagnosed with PD according to the UK PD Society Brain Bank criteria (Hughes et al., 1992) 3. On L-dopa treatment during the time of the study 4. Responsive to L-dopa with more than 25% reductions in Unified PD Rating Scale (UPDRS) part III motor scores 5. More than 6 months on L-DOPA 6. Non-demented [mini?mental state examination (MMSE = 26] 7. No psychiatric disorders as screened with a structured clinical interview for DSM-IV Axis I Disorders (SCID-I) 8. Do not fail screening for depression [Beck Depression Inventory - II (BDI-II) < 17; Hamilton Rating Scale for Depression (HRSD) < 14] 9. None of the subjects had received anti-depressant therapy in the past or any other medication with known action on the serotonergic system 10. No more than 1.5 body mass index (BMI) units changes over the last 12 months Healthy individuals 1. Age between 50-80 2. Non-demented (MMSE = 26) 3. No psychiatric disorders as screened with a structured clinical interview for DSM-IV Axis I Disorders (SCID-I) 4. Do not fail screening for depression (BDI-II < 17; HRSD < 14) 5. None of the subjects had received anti-depressant therapy in the past or any other medication with known action on the serotonergic system 6. No more than 1.5 BMI units changes over the last 12 months 7. Were not on any medication 8. No previous history of neurological or psychiatric illness
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Dyskinesias assesments with Abnormal Involuntary Movement Scale (AIMS) 2. Reduction of abnormal dopamine release in the striatum of Parkinson's disease patients as measured with PET Measured 150 minutes following administration of medication. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in motor function as measured with Unified Parkinson's Disease Rating Scale (UPDRS) part III motor scale measured 150 minutes following administration of medication. | — |
Countries
United Kingdom
Outcome results
None listed